Genetic test-guided treatment for newly diagnosed peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have peripheral T-cell lymphoma confirmed by biopsy (tissue sample).
- You can provide lymphoma tumor tissue (stored or newly collected) that’s enough for genetic testing.
- You have at least one measurable spot that doctors can track on a PET-CT or CT scan.
- Your general health is good enough for treatment (ECOG 0–2) and you’re expected to live at least 3 months.
- You can sign informed consent, and your blood and organ test results are within required limits (unless abnormal due to lymphoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This study tests whether adding a targeted drug called linperlisib to the standard chemo regimen (CHOP) is better than CHOP alone for people with newly diagnosed peripheral T-cell lymphoma. It may help shrink tumors and control the lymphoma for longer.
This study is testing whether a treatment chosen based on your tumor's genetic makeup works better than a standard one for people newly diagnosed with peripheral T-cell lymphoma. The goal is to find a more personalized approach that targets your specific cancer.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.